Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...

Initial $50M Series A investment from founding investor RTW InvestmentsProceeds will fund clinical development of PRO-203 in systemic sclerosis ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with systemic sclerosis will likely require multidisciplinary management with combination ...

LA JOLLA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc. (MNOV), a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange (Code ...

DUBLIN--(BUSINESS WIRE)--The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The value of the global scleroderma ...

Fibrosis, or the scaring of tissue, occurs in many diseases, and is a central component of systemic sclerosis. There are currently no treatments that can reverse fibrosis and the current treatment ...

Alicia M. Hinze, MD: The goal in therapy for interstitial lung disease that is progressing and systemic sclerosis would be stabilization of disease. Unfortunately, we don’t have something that is ...

The drug tofacitinib was well tolerated among patients with early scleroderma, primarily affecting the protein interferon both in fibroblasts and keratinocytes. Researchers say the drug is safe and ...